Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Izzotti, Alberto; Ceccaroli, Chiara; Geretto, Marta; Ruggieri, F; Schenone, Sara; Maria, Emilio Di

doi:10.3390/cancers12061652

Cited by 15 publications

(12 citation statements)

References 108 publications

(209 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several gene expression signatures have been published [63][64][65][66][67]. In a recent review Izzotti et al summarized the current knowledge on genetic and epigenetic biomarkers used as predictors of response following nCRT [68]. After an extensive review of the literature, only 19 mRNAs and 6 miRNAs were found to be expressed differentially among responders versus non-responders in two or more independent studies.…”

Section: Assessment Of Response To Ncrtmentioning

confidence: 99%

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

et al. 2022

View full text Add to dashboard Cite

Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local and distal recurrences and a high-risk of poor quality of life (QoL). Over the last three decades, advances in screening tests, therapies, and combined-modality treatment options and strategies have improved the prognosis of patients with LARC. However, owing to the heterogeneous nature of LARC and genetic status, the patient may not respond to a specific therapy and may be at increased risk of side-effects without the life-prolonging benefit. Indeed, each therapy can cause its own side-effects, which may worsen by a combination of treatments resulting in long-term poor QoL. In LARC, QoL has become even more essential with the increasing www.oncotarget.com incidence of rectal cancer in young individuals. Herein, we analyzed the value of the Immunoscore-Biopsy (performed on tumor biopsy at diagnosis) in predicting outcomes, alone or in association with clinical and imaging data, for each therapy used in LARC.

show abstract

Section: Assessment Of Response To Ncrtmentioning

confidence: 99%

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 163 Several differentially expressed miRNAs in rectal cancer were reported as biomarkers that can predict response to nCRT. 164 , 165 For instance, expression level of miR-21, a well-characterized miRNA, was found to discriminate between complete responders and noncomplete responders in rectal cancer. 166 , 167 However, while one study demonstrated that overexpression of miR-21-5p was associated with complete regression after nCRT, 166 another study found the opposite.…”

Section: Introductionmentioning

confidence: 99%

Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models

Xiao

Venkatachalam

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is commonly applied to treat locally advanced rectal cancer (LARC). In this review, we summarize current and novel concepts of neoadjuvant therapy for LARC such as total neoadjuvant therapy and describe how these developments impact treatment response. Moreover, as response to nCRT is highly divergent in rectal cancers, we discuss the role of potential predictive biomarkers. We review recent advances in biomarker discovery, from a clinical as well as a histopathological and molecular perspective. Furthermore, the role of emerging predictive biomarkers derived from the tumor environment such as immune cell composition and gut microbiome is presented. Finally, we describe how different tumor models such as patient-derived cancer organoids are used to identify novel predictive biomarkers for chemoradiotherapy (CRT) in rectal cancer.

show abstract

“…EVs form includes microvesicles and exosomes that represent the common form of released extracellular miRNAs [30,65,68,69]. Nevertheless, miRNAs show the features of an ideal biomarker being available in body fluids, tissue-and disease-specificities, extremely stable and easily collected and detected using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) [40,[76][77][78][79]. The identification of circulating miRNAs opened the possibility to use them as biomarkers to understand their role in human health or diseases [80].…”

Section: Circulating Mirnasmentioning

confidence: 99%

Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions

Sarshar

Scribano

Ambrosi

et al. 2020

Cancers

View full text Add to dashboard Cite

Over the past decade, short non-coding microRNAs (miRNAs), including circulating and fecal miRNAs have emerged as important modulators of various cellular processes by regulating the expression of target genes. Recent studies revealed the role of miRNAs as powerful biomarkers in disease diagnosis and for the development of innovative therapeutic applications in several human conditions, including intestinal diseases. In this review, we explored the literature and summarized the role of identified dysregulated fecal miRNAs in intestinal diseases, with particular focus on colorectal cancer (CRC) and celiac disease (CD). The aim of this review is to highlight one fascinating aspect of fecal miRNA function related to gut microbiota shaping and bacterial metabolism influencing. The role of miRNAs as “messenger” molecules for inter kingdom communications will be analyzed to highlight their role in the complex host-bacteria interactions. Moreover, whether fecal miRNAs could open up new perspectives to develop novel suitable biomarkers for disease detection and innovative therapeutic approaches to restore microbiota balance will be discussed.

show abstract

Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Cited by 15 publications

References 108 publications

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life?

Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models

Fecal microRNAs as Innovative Biomarkers of Intestinal Diseases and Effective Players in Host-Microbiome Interactions

Contact Info

Product

Resources

About